This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Adaptimmune Therapeutics’s 8K filing here.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
- Five stocks we like better than Adaptimmune Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Rocket Lab is the Right Stock for the Right Time
- High Flyers: 3 Natural Gas Stocks for March 2022
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- About the Markup Calculator
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
